Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma
Abstract
Radiotherapy is increasingly combined with CAR T cell therapy in B cell lymphomas, but treatment outcome may depend on the irradiation modality. We evaluated minibeam radiation therapy (MBRT) as a partner for CD19 CAR T cells in an orthotopic primary central nervous system (CNS) lymphoma model in immunodeficient rats. CAR T therapy prolonged survival compared with untreated controls. MBRT at 30 Gy followed by CAR T cells five days later produced the longest median survival among radiotherapy-containing regimens and improved outcome compared with conventional radiotherapy (CRT) based combinations. Histopathological findings were consistent with these survival differences. However, MBRT plus CAR T therapy did not significantly outperform CAR T monotherapy. These results indicate that MBRT provides a favorable, non-antagonistic radiotherapy context for CAR T therapy and suggest that radiation modality should be considered when designing combinations of radiotherapy with adoptive cellular therapies.
Related
- Mitochondrial rewiring supports survival of triple negative breast cancer cells after ionizing radiation
- 251 Product characterization of a clinical-grade BCMA CAR-MIL therapy supports IND-enabling development for multiple myeloma
- PINK1-mediated mitophagy supports lung cancer initiation and limits the efficacy of KRAS -targeted therapy
- From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma
- Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial
BibTeX
@article{iturri2026minibeam,
title = {{Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma}},
author = {Lorea Iturri and Sarah Potiron and Liangchao Sun and Marjorie Juchaux and Cristèle Gilbert and Julie Espenon and Ignacio Anegon and Severine Ménoret and Carole Soussain and Sebastián Amigorena and Marion Alcantara and Yolanda Prezado},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117827},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03208-6},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma
AU - Lorea Iturri
AU - Sarah Potiron
AU - Liangchao Sun
AU - Marjorie Juchaux
AU - Cristèle Gilbert
AU - Julie Espenon
AU - Ignacio Anegon
AU - Severine Ménoret
AU - Carole Soussain
AU - Sebastián Amigorena
AU - Marion Alcantara
AU - Yolanda Prezado
PY - 2026
DA - 2026/10/08
JO - iScience
DO - 10.1016/j.isci.2026.117827
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03208-6
AB - Radiotherapy is increasingly combined with CAR T cell therapy in B cell lymphomas, but treatment outcome may depend on the irradiation modality. We evaluated minibeam radiation therapy (MBRT) as a partner for CD19 CAR T cells in an orthotopic primary central nervous system (CNS) lymphoma model in immunodeficient rats. CAR T therapy prolonged survival compared with untreated controls. MBRT at 30 Gy followed by CAR T cells five days later produced the longest median survival among radiotherapy-containing regimens and improved outcome compared with conventional radiotherapy (CRT) based combinations. Histopathological findings were consistent with these survival differences. However, MBRT plus CAR T therapy did not significantly outperform CAR T monotherapy. These results indicate that MBRT provides a favorable, non-antagonistic radiotherapy context for CAR T therapy and suggest that radiation modality should be considered when designing combinations of radiotherapy with adoptive cellular therapies.
SN - 2589-0042
ER -